Dr. Carpenter has over 25 years of experience in medicine, basic science and clinical research and pharmaceutical drug development including leading several successful IND, NDA and sNDA submissions. He has held a number of leadership positions in the pharmaceutical and biotechnology industries including President and Chief Executive Officer of Sention, Vice-President of Clinical Research & Development and Regulatory Affairs at Adolor Corporation and member of the Global Therapeutic Area Team at Astra Pain Control. Prior to joining industry, he held academic faculty appointments at the University of Washington and Wake Forest University. Dr. Carpenter is the author of more than 70 peer-reviewed articles, holds several patents and has served as editor-in-chief or on the editorial boards of several medical journals. He received the Pioneer Award from the FRAXA Research Foundation in 2010 for his efforts to translate basic science discoveries into novel therapeutics for individuals with fragile X syndrome.

Dr. Amedio has 22 years of experience in major and start-up pharmaceutical companies. He has extensive experience in all aspects of chemistry, manufacturing and controls (CMC), including regulatory agency document preparation, quality assurance, active pharmaceutical ingredient synthesis, drug product pre-formulation and formulation, analytical methods development and the preparation of clinical trial material for the appropriate developmental stage worldwide. Dr. Amedio has delivered numerous profitable and patented manufacturing processes for active pharmaceutical ingredients and finished drug product (injectable and oral dosage forms). He is the author and co-author of several peer-reviewed articles, publications and patents and has given numerous invited presentations. Prior to joining Seaside Therapeutics, Dr. Amedio was Vice President, Manufacturing & Process Development, ZIOPHARM Oncology, Inc., Executive Director, Analytical and Chemical R&D, EPIX Pharmaceuticals Inc. and Unit Leader, Chemical Research and Development Department, Sandoz Research Institute (currently Novartis Pharmaceuticals). Dr. Amedio completed his PhD in Organic Chemistry from the University of Delaware and completed post-doctoral research at Oregon State University.

Dr. Healy has over 15 years of experience in disease biology, leading independent research efforts in the areas of neuroscience, cardiovascular pathophysiology, oncology and inflammation. From 2001 until 2008, Dr. Healy held positions of increasing responsibility at Momenta Pharmaceuticals and Millennium Pharmaceuticals. Her prior preclinical research in drug discovery and development included significant contributions to target identification, lead optimization, in vivo pharmacology and biomarker discovery for small molecules and biologics. Before taking those positions, Dr. Healy was a faculty member at Boston University School of Medicine, where her research focused on cellular and molecular mechanisms of pulmonary development and disease. Dr. Healy holds patents and has published in peer-reviewed journals on a wide range of topics including biomarkers and the molecular mechanisms of disease. Dr. Healy received her PhD in cellular biology at Tufts University Medical School and completed her postdoctoral training in the molecular biology of the blood vessel wall at the Massachusetts Institute of Technology.

Dr. Rush contributes over 30 years of international experience in pharmaceutical research and development to Seaside. His major career focus has been on preclinical research and development, particularly the transition of discovery research candidates into clinical development where he has provided drug metabolism, pharmacokinetics and preclinical drug safety evaluation expertise. Throughout his career he has contributed to numerous drug registration dossiers including Investigational New Drug Applications, Clinical Trial Authorizations, New Drug Applications and Marketing Authorization Applications. He joined Seaside Therapeutics from Wolfe Laboratories, Inc., where he was Vice President, Preclinical Development. His prior experience also includes senior management positions at Critical Therapeutics, Inc., Roche Palo Alto LLC, Scotia Pharmaceuticals (acquired by QuantaNova Ltd) and Quintiles Scotland Ltd. Dr. Rush holds a BSc and a PhD both in Biochemistry from the University of Surrey in the UK. 

Dr. Wang is a developmental-behavioral pediatrician who brings 20 years of experience in neurodevelopmental disorders and pediatric drug development to Seaside. Dr. Wang was previously a Senior Director in Clinical Development at Pfizer, where he provided leadership on multiple pediatric projects. Prior to Pfizer, Dr. Wang was on the faculty of the University of Pennsylvania and Children's Hospital of Philadelphia where his work focused on language and memory development, especially in children with genetic diagnoses. Dr. Wang has authored more than 25 peer-reviewed publications and continues to work on review and advisory panels for the NIH, Autism Speaks, and other groups. Dr. Wang holds leadership roles in several professional and advocacy groups, including the Society for Developmental-Behavioral Pediatrics and the American Academy of Pediatrics, and he previously served on the American Board of Pediatrics. Dr. Wang was educated at Harvard College and at Yale University School of Medicine.  His clinical and research training were at the University of Michigan, the Salk Institute, and Children’s Seashore House in Philadelphia. 

Mr. Zarevics brings more than 30 years of domestic and international drug development experience and a diverse, multi-disciplinary background spanning preclinical neuropharmacology, medical writing, clinical research operations and infrastructure engineering/re-engineering. During his career, Mr. Zarevics has worked in diverse environments including large pharmaceutical companies (SmithKline Beecham, Merck), a rapidly expanding new company (Astra Merck), a contract research organization (G.H. Besselaar, now Covance), biotechnology (Stressgen Biotechnologies, Sention) and as an independent consultant. Mr. Zarevics has participated in more than 10 NDA, sNDA and MAA engagements over multiple therapeutic areas including the central nervous system. Mr. Zarevics is a graduate of the University of Pennsylvania.